EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Large‐Scale, Retrospective Analysis of Bath‐Psoralen Plus Ultraviolet A Therapy for Psoriasis: A Single‐Center Study

Mai Sakurai, Yuki Enomoto, Yoshifumi Kanayama, Takashi Sakaida, Aya Yamamoto, Akimichi Morita iD

Photodermatology, Photoimmunology & Photomedicine · 2025

DOI: 10.1111/phpp.70038 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Photodermatology, Photoimmunology & Photomedicine, 2025. Verfasst von Mai Sakurai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. Hauptthemen laut MEDLINE: Psoriasis, PUVA Therapy, Ficusin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Purpose While biologics and small‐molecule inhibitors are first‐line systemic treatments for psoriasis, phototherapy remains an alternative for patients unable to access these treatments because of medical or financial constraints. Narrow‐band ultraviolet B (NB‐UVB) is effective for localized psoriasis but less so for extensive disease. To address this limitation, bathwater delivery of psoralen plus ultraviolet A (bath‐PUVA) was introduced in 2004. This study evaluates the efficacy, safety, and patient characteristics associated with bath‐PUVA therapy in a large cohort.

Methods

This retrospective analysis included 229 patients (180 males, 49 females) treated with bath‐PUVA from 2004 to September 2021. Baseline characteristics and treatment outcomes were assessed using the psoriasis area and severity index (PASI). Statistical analyses examined relationships between treatment outcomes and factors, including baseline PASI, body mass index (BMI), and smoking status.

Results

The mean baseline PASI score was 24.9. Bath‐PUVA achieved PASI 75 in 80.4% of patients, PASI 90 in 44.1%, and PASI 100 in 2.6%, with efficacy comparable to biologics. Patients achieving PASI 90 had significantly higher baseline PASI scores ( p = 0.005), while the number of irradiations required did not differ ( p = 0.692). Higher baseline PASI scores correlated with elevated BMI ( p = 0.002), but BMI did not influence improvement rates ( p = 0.094). Smokers had significantly higher baseline PASI scores ( p = 0.004) compared with non‐smokers, yet smoking status did not affect improvement rates ( p = 0.862).

Conclusion

Bath‐PUVA demonstrates efficacy comparable with biologics for psoriasis, regardless of BMI or smoking status. This analysis supports its use as an effective and accessible treatment option for patients with extensive disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisPUVA TherapyFicusinHumansMaleFemaleRetrospective StudiesMiddle AgedAdultAgedSeverity of Illness Index

Stichwörter der Autor:innen

bath‐PUVA (bath‐psoralen plus ultraviolet a therapy)phototherapypsoriasis

Substanzen

Ficusin

Autor:innen und Institutionen

  • Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

ORCID-Profile: Akimichi Morita

Zitieren

APA

Sakurai, M., Enomoto, Y., Kanayama, Y., Sakaida, T., Yamamoto, A., & Morita, A. (2025). A Large‐Scale, Retrospective Analysis of Bath‐Psoralen Plus Ultraviolet A Therapy for Psoriasis: A Single‐Center Study. Photodermatology, Photoimmunology & Photomedicine. https://doi.org/10.1111/phpp.70038

Vancouver

Sakurai M, Enomoto Y, Kanayama Y, Sakaida T, Yamamoto A, Morita A. A Large‐Scale, Retrospective Analysis of Bath‐Psoralen Plus Ultraviolet A Therapy for Psoriasis: A Single‐Center Study. Photodermatology, Photoimmunology & Photomedicine. 2025. doi:10.1111/phpp.70038

BibTeX
@article{Sakurai2025,
  author = {Sakurai, Mai and Enomoto, Yuki and Kanayama, Yoshifumi and Sakaida, Takashi and Yamamoto, Aya and Morita, Akimichi},
  title = {A Large‐Scale, Retrospective Analysis of Bath‐Psoralen Plus Ultraviolet A Therapy for Psoriasis: A Single‐Center Study},
  journal = {Photodermatology, Photoimmunology & Photomedicine},
  year = {2025},
  doi = {10.1111/phpp.70038}
}
Kostenlos starten →